NCT03229174View on ClinicalTrials.gov

Brain Perfusion & Oxygenation in Parkinson's Disease With NOH

PHASE4CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

August 23, 2018

Primary Completion Date

February 2, 2022

Study Completion Date

February 2, 2022

Conditions
Parkinson DiseaseNeurogenic Orthostatic Hypotension
Interventions
DRUG

Droxidopa

Droxidopa initial dose 100mg TID, titrated in increments of 100mg every 24-48 hours to symptomatic response.

DRUG

Placebo

Placebo (sugar pill)

Trial Locations (1)

77030

Houston Methodist Hospital, Houston

Sponsors

Collaborators (1)

Lundbeck LLC
All Listed Sponsors
collaborator

Lundbeck LLC

INDUSTRY

lead

William Ondo, MD

OTHER